Latest Headlines

  1. Bluestar Genomics Receives CLIA Certification For Its Clinical Laboratory 6/6/2022

    Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy tests initially focused on non-invasive detection of high-mortality cancers in high-risk patient populations through a standard blood draw, today announced it has received Clinical Laboratory Improvement Amendments (CLIA) certification from the U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid Services.

  2. Bruker Announces Key Innovations For Highly Multiplexed Spatial Proteomics And Multiomic Tissue Imaging At Large Field-Of-View 6/6/2022

    At the 70th ASMS Conference, Bruker Corporation announced key innovations for spatial multiomics of tissue and tumor microenvironments (TME). Following Bruker’s strategic partnership with AmberGen1, key enhancements are introduced for MALDI HiPLEX-IHC mass spectrometry imaging.

  3. Tempus To Launch Largest Clinically Available Liquid Biopsy Panel, xF+ 6/3/2022

    Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its comprehensive genomic profiling offerings with xF+, a new non-invasive, liquid biopsy panel of 523 genes, focused on pathogenic mutations in cell-free DNA (cfDNA).

  4. U.S. CDC Endorses The Use Of Digital PCR Technology For Wastewater Surveillance Of Infectious Diseases – Including COVID-19 Outbreaks 6/1/2022

    QIAGEN N.V. today announced that it welcomed an endorsement from the National Wastewater Surveillance System (NWSS) of the U.S. Centers for Disease Control and Prevention (CDC) and their validation and approval for the use of two digital PCR systems – including the QIAcuity digital PCR system – for wastewater surveillance of 30 pathogens, including the SARS-CoV-2 virus.

  5. Genetron Health Receives CE Mark For FusionScan Plus Kit For Human Multi-Genes 6/1/2022

    Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced it has obtained a CE Mark for its FusionScan Plus Kit, an integrated DNA and RNA NGS-based assay for simultaneously detecting multiple gene mutations and fusions with lower thresholds, (Registration number: DE/CA20/01-IVD-Luxuslebenswelt-886/22).

  6. Burning Rock Receives CE Mark For Its OverC™ Multi-Cancer Detection Blood Test Kit 6/1/2022

    Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock") announced that it has received CE marking for its OverC™ Multi-Cancer Detection Blood Test manufactured in both the US and China facilities (Identification Number: DE/CA20/01-IVD-Luxuslebenswelt-523/22, DE/CA20/01-IVD-Luxuslebenswelt-524/22).

  7. OneCellDx And Genetics Institute Of America Partner To Launch OncoPredikt HRD Assay 5/31/2022

    OneCellDx and Genetics Institute of America announced today that they have signed a memorandum of understanding for a diagnostics commercialization agreement for the OneCellDx OncoPredikt HRD Assay.

  8. GRAIL Announces Collaboration With U.S. Department Of Veterans Affairs And The Veterans Health Foundation To Evaluate Galleri Multi-Cancer Early Detection Test 5/31/2022

    GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today a collaboration with the U.S. Department of Veterans Affairs (VA) Veterans Health Administration, America’s largest integrated health care system, and the Veterans Health Foundation to provide Galleri, GRAIL’s groundbreaking multi-cancer early detection (MCED) blood test, to 10,000 veterans across approximately 10 participating VA sites over the next three years.

  9. Sectra Signs Framework Agreement To Supply Public Hospitals In France With Imaging IT For Digital Pathology 5/31/2022

    International medical imaging IT and cybersecurity company Sectra (STO: SECT B) and UniHA, a cooperative of French public hospitals, have signed a framework agreement for Sectra Digital Pathology.

  10. Volition Achieves CE Mark For Nu.Q® NETs Test 5/31/2022

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® NETs test has been CE marked for the detection and evaluation of NETosis, enabling clinical use in more than 27 countries across Europe.